Incyte Reports 2023 First Quarter Financial Results and Provides Updates on Key Clinical ProgramsBusiness Wire • 05/02/23
Incyte Announces Results from SCRATCH-AD Trial Demonstrating Substantial and Rapid Itch Reduction in Patients with Mild-Moderate Atopic Dermatitis Treated with Opzelura® (ruxolitinib) CreamBusiness Wire • 05/01/23
Incyte (INCY) Earnings Expected to Grow: What to Know Ahead of Next Week's ReleaseZacks Investment Research • 04/25/23
Incyte Announces European Commission Approval of Opzelura® (ruxolitinib) Cream for the Treatment of Non-Segmental Vitiligo with Facial Involvement in Adults and AdolescentsBusiness Wire • 04/20/23
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Incyte Corporation - INCYPRNewsWire • 04/19/23
S&P 500 Stocks: Micron, Charles Schwab Among Top Performers MondayInvestors Business Daily • 04/10/23
Incyte Announces Japanese Approval of Pemazyre® (pemigatinib) for the Treatment of Patients with Myeloid/Lymphoid Neoplasms (MLNs)Business Wire • 03/27/23
Incyte Announces FDA Approval of Zynyz™ (retifanlimab-dlwr) for the Treatment of Metastatic or Recurrent Locally Advanced Merkel Cell Carcinoma (MCC)Business Wire • 03/22/23
Incyte Announces Data from Phase 2b Study Evaluating Povorcitinib (INCB54707) in Patients with Extensive Nonsegmental VitiligoBusiness Wire • 03/18/23
Incyte Announces Long-Term Extension Data from Phase 3 TRuE-V Program Demonstrating Long-Term Safety and Durability of Response of Opzelura® (Ruxolitinib) Cream in VitiligoBusiness Wire • 03/18/23
Incyte Announces Data from Across its Oncology Portfolio will be Presented at the AACR Annual Meeting 2023Business Wire • 03/14/23